^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    ARGX-111

    i
    Other names: ARGX-111, ARGX 111
    Associations

    News

    Trials
    Company:
    argenx
    Drug class:
    c-MET inhibitor
    Related drugs:
    Associations

    News

    Trials
    over3years
    The NHance Mutation-Equipped Anti-MET Antibody ARGX-111 Displays Increased Tissue Penetration and Anti-Tumor Activity in Advanced Cancer Patients. (PubMed, Biomedicines)
    When escalated to 1 mg/kg, a partial response was reached. Furthermore, decreased numbers of CTC (75%) possibly by the enhanced tumor cell killing witnessed the modes of action of the drug, warranting further clinical investigation of ARGX-111.
    Clinical • Journal
    |
    MET (MET proto-oncogene, receptor tyrosine kinase)
    |
    MET amplification • MET mutation
    |
    ARGX-111